News Briefs
Recombinant human Relaxin disappoints in Scleroderma trial
In a study of patients with systemic sclerosis with diffuse cutaneous involvement, treatment with recombinant human relaxin did not improve skin disease or reduce functional disability....
Want to read complete article? Please Sign in or Register.